JP2004504057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504057A5 JP2004504057A5 JP2002513918A JP2002513918A JP2004504057A5 JP 2004504057 A5 JP2004504057 A5 JP 2004504057A5 JP 2002513918 A JP2002513918 A JP 2002513918A JP 2002513918 A JP2002513918 A JP 2002513918A JP 2004504057 A5 JP2004504057 A5 JP 2004504057A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- hpv
- polypeptide
- encoding
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002157 polynucleotide Substances 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 20
- 102000040430 polynucleotide Human genes 0.000 description 20
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 206010008263 Cervical dysplasia Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 5
- 206010059313 Anogenital warts Diseases 0.000 description 4
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 208000000907 Condylomata Acuminata Diseases 0.000 description 4
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 3
- 201000004201 anogenital venereal wart Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- -1 Amino Chemical group 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102220274708 rs1555866028 Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0017990.3A GB0017990D0 (en) | 2000-07-21 | 2000-07-21 | Papilloma virus sequences |
| GB0025802A GB0025802D0 (en) | 2000-10-20 | 2000-10-20 | Papilloma virus sequences |
| PCT/GB2001/003290 WO2002008435A1 (en) | 2000-07-21 | 2001-07-20 | Codon-optimized papilloma virus sequences |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004504057A JP2004504057A (ja) | 2004-02-12 |
| JP2004504057A5 true JP2004504057A5 (enExample) | 2008-09-11 |
Family
ID=26244703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513918A Pending JP2004504057A (ja) | 2000-07-21 | 2001-07-20 | コドン最適化されたパピローマウイルス配列 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1301614B1 (enExample) |
| JP (1) | JP2004504057A (enExample) |
| KR (1) | KR100874552B1 (enExample) |
| CN (1) | CN1262665C (enExample) |
| AT (1) | ATE346947T1 (enExample) |
| AU (2) | AU7569501A (enExample) |
| BR (1) | BR0112637A (enExample) |
| CA (1) | CA2416488A1 (enExample) |
| CY (1) | CY1106334T1 (enExample) |
| CZ (1) | CZ2003180A3 (enExample) |
| DE (1) | DE60124918T2 (enExample) |
| DK (1) | DK1301614T3 (enExample) |
| ES (1) | ES2277605T3 (enExample) |
| HK (1) | HK1056195B (enExample) |
| HU (1) | HUP0300745A3 (enExample) |
| IL (1) | IL154009A0 (enExample) |
| MX (1) | MXPA03000554A (enExample) |
| NO (1) | NO20030219L (enExample) |
| NZ (1) | NZ523683A (enExample) |
| PL (1) | PL365385A1 (enExample) |
| PT (1) | PT1301614E (enExample) |
| WO (1) | WO2002008435A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1857122E (pt) * | 2001-06-05 | 2011-03-07 | Curevac Gmbh | Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral |
| WO2003018055A1 (en) * | 2001-08-23 | 2003-03-06 | Merck & Co., Inc. | Vaccine using papilloma virus e proteins delivered by viral vector |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| AU2003217413A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| NZ542246A (en) | 2003-03-24 | 2007-12-21 | Merck & Co Inc | Optimized expression of HPV 31 L1 yeast |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| US7700103B2 (en) | 2004-03-24 | 2010-04-20 | Merck & Co., Inc. | Optimized expression of HPV 52 L1 in yeast |
| GB0617387D0 (en) * | 2006-09-04 | 2006-10-11 | Glaxo Group Ltd | Synthetic gene |
| US8772256B2 (en) * | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
| GB0700914D0 (en) * | 2007-01-18 | 2007-02-28 | Animal Health Inst | Polynucleotides and uses thereof |
| CA2675355C (en) | 2007-01-30 | 2015-04-28 | Transgene S.A. | Papillomavirus vaccine |
| MX2009010549A (es) | 2007-03-30 | 2010-03-15 | Univ New York State Res Found | Virus atenuados utiles para vacunas. |
| GB0710538D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Vaccine |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2925021C (en) | 2013-11-01 | 2025-05-06 | Curevac Ag | MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES |
| WO2017075571A1 (en) | 2015-10-30 | 2017-05-04 | Children's National Medical Center | Generating hpv antigen-specific cells from a naive t cell population |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| EA201891001A1 (ru) | 2015-10-22 | 2018-11-30 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv) |
| EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464936A (en) * | 1990-12-21 | 1995-11-07 | Cetus Oncology Corporation | Compositions for identification of papillomavirus replication inhibitors |
| DE4123760C2 (de) * | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
| IL131131A0 (en) * | 1997-02-07 | 2001-01-28 | Merck & Co Inc | Synthetic hiv gag genes |
| AU766403C (en) * | 1998-09-04 | 2004-05-27 | Aventis Pasteur Limited | Treatment of cervical cancer |
| JP4799789B2 (ja) * | 1999-08-25 | 2011-10-26 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 |
-
2001
- 2001-07-20 AU AU7569501A patent/AU7569501A/xx active Pending
- 2001-07-20 HK HK03106686.3A patent/HK1056195B/en not_active IP Right Cessation
- 2001-07-20 DE DE60124918T patent/DE60124918T2/de not_active Expired - Fee Related
- 2001-07-20 PT PT01953199T patent/PT1301614E/pt unknown
- 2001-07-20 NZ NZ523683A patent/NZ523683A/en unknown
- 2001-07-20 DK DK01953199T patent/DK1301614T3/da active
- 2001-07-20 AU AU2001275695A patent/AU2001275695B9/en not_active Ceased
- 2001-07-20 AT AT01953199T patent/ATE346947T1/de not_active IP Right Cessation
- 2001-07-20 MX MXPA03000554A patent/MXPA03000554A/es active IP Right Grant
- 2001-07-20 IL IL15400901A patent/IL154009A0/xx unknown
- 2001-07-20 WO PCT/GB2001/003290 patent/WO2002008435A1/en not_active Ceased
- 2001-07-20 CN CNB018161081A patent/CN1262665C/zh not_active Expired - Fee Related
- 2001-07-20 KR KR1020037000847A patent/KR100874552B1/ko not_active Expired - Fee Related
- 2001-07-20 HU HU0300745A patent/HUP0300745A3/hu unknown
- 2001-07-20 EP EP01953199A patent/EP1301614B1/en not_active Expired - Lifetime
- 2001-07-20 ES ES01953199T patent/ES2277605T3/es not_active Expired - Lifetime
- 2001-07-20 BR BR0112637-7A patent/BR0112637A/pt not_active Application Discontinuation
- 2001-07-20 PL PL01365385A patent/PL365385A1/xx unknown
- 2001-07-20 JP JP2002513918A patent/JP2004504057A/ja active Pending
- 2001-07-20 CZ CZ2003180A patent/CZ2003180A3/cs unknown
- 2001-07-20 CA CA002416488A patent/CA2416488A1/en not_active Abandoned
-
2003
- 2003-01-16 NO NO20030219A patent/NO20030219L/no not_active Application Discontinuation
-
2007
- 2007-02-21 CY CY20071100246T patent/CY1106334T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504057A5 (enExample) | ||
| JP2004512264A5 (enExample) | ||
| US6066324A (en) | Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles | |
| AU729336B2 (en) | Vaccine | |
| KR101170654B1 (ko) | 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현 | |
| JP2006501825A5 (enExample) | ||
| TWI731300B (zh) | 一種新型多價hpv 疫苗成份 | |
| US20080138361A1 (en) | Optimized expression of HPV 45 L1 in yeast | |
| KR101203403B1 (ko) | 효모에서 ｈｐｖ 52 ｌ1의 최적화된 발현 | |
| JP2000511773A (ja) | 核酸を送達するベクターとして有用なウイルス様粒子 | |
| CN101952320B (zh) | 具有免疫原性的物质 | |
| CN107249627B (zh) | 含有来自hpv e7蛋白质的多肽的乳酸菌的组合物 | |
| CN103936840B (zh) | 重组的人乳头瘤病毒33型l1蛋白及其用途 | |
| CN116041444A (zh) | 人乳头瘤病毒hpv39 l1蛋白的表达和类病毒样颗粒及其制备方法 | |
| US7314629B2 (en) | Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus | |
| KR20210018351A (ko) | 타입 39 인유두종 바이러스 l1 단백질의 돌연변이체 | |
| EP2377879A1 (en) | N-terminal HPV E7 fusion proteins | |
| CN101181636A (zh) | 一种防治人乳头瘤病毒感染的复方疫苗组合物、复方疫苗阴道喷雾剂及其用途 | |
| RU2354701C2 (ru) | Полинуклеотидная последовательность, кодирующая полипептид вируса папилломы человека, ее применение, а также содержащие ее вектор и фармацевтическая композиция | |
| CN116102627A (zh) | 人乳头瘤病毒hpv35 l1蛋白的表达和类病毒样颗粒及其制备方法 | |
| JP2002532434A5 (enExample) | ||
| JP2006516386A5 (enExample) | ||
| KR20200035963A (ko) | 인간 유두종 바이러스 타입 16의 l1 단백질의 변이체 | |
| CN112316130A (zh) | 一种SARS-CoV2粘膜免疫疫苗及其应用 | |
| EP3241848A1 (en) | Construction method for recombinant vaccine having anti-cervical cancer cell activity and application thereof |